• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Nove

tetano

Editor, Senior Moderator
Front Microbiol. 2016 Mar 7;7:262. doi: 10.3389/fmicb.2016.00262. eCollection 2016.
[h=1]Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Novel PB1-F2 Polymorphisms.[/h] Zaraket H[SUP]1[/SUP], Kondo H[SUP]2[/SUP], Hibino A[SUP]2[/SUP], Yagami R[SUP]2[/SUP], Odagiri T[SUP]2[/SUP], Takemae N[SUP]3[/SUP], Tsunekuni R[SUP]3[/SUP], Saito T[SUP]3[/SUP]; Japanese Influenza Collaborative Study Group, Myint YY[SUP]4[/SUP], Kyaw Y[SUP]5[/SUP], Oo KY[SUP]6[/SUP], Tin HH[SUP]6[/SUP], Lin N[SUP]7[/SUP], Anh NP[SUP]8[/SUP], Hang Nle K[SUP]8[/SUP], Mai le Q[SUP]8[/SUP], Hassan MR[SUP]9[/SUP], Shobugawa Y[SUP]2[/SUP], Tang J[SUP]10[/SUP], Dbaibo G[SUP]11[/SUP], Saito R[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A viruses evolve at a high rate requiring continuous monitoring to maintain the efficacy of vaccines and antiviral drugs. We performed next generation sequencing analysis of 100 influenza A/H3N2 isolates collected in four Asian countries (Japan, Lebanon, Myanmar, and Vietnam) during 2012-2015. Phylogenetic analysis revealed several reassortment events leading to the circulation of multiple clades within the same season. This was particularly evident during the 2013 and 2013/2014 seasons. Importantly, our data showed that certain lineages appeared to be fitter and were able to persist into the following season. The majority of A/H3N2 viruses continued to harbor the M2-S31N mutation conferring amantadine-resistance. In addition, an S31D mutation in the M2-protein, conferring a similar level of resistance as the S31N mutation, was detected in three isolates obtained in Japan during the 2014/2015 season. None of the isolates possessed the NA-H274Y mutation conferring oseltamivir-resistance, though a few isolates were found to contain mutations at the catalytic residue 151 (D151A/G/N or V) of the NA protein. These variations did not alter the susceptibility to neuraminidase inhibitors and were not detected in the original clinical specimens, suggesting that they had been acquired during their passage in MDCK cells. Novel polymorphisms were detected in the PB1-F2 open-reading frame resulting in truncations in the protein of 24-34 aminoacids in length. Thus, this study has demonstrated the utility of monitoring the full genome of influenza viruses to allow the detection of the potentially fittest lineages. This enhances our ability to predict the strain(s) most likely to persist into the following seasons and predict the potential degree of vaccine match or mismatch with the seasonal influenza season for that year. This will enable the public health and clinical teams to prepare for any related healthcare burden, depending on whether the vaccine match is predicted to be good or poor for that season.


[h=4]KEYWORDS:[/h] PB1-F2; antiviral; evolution; full-genome; influenza A/H3N2; phylogenetic analysis; reassortment; vaccine

PMID: 27014195 [PubMed] PMCID: PMC4779883 Free PMC Article
 
Back
Top Bottom